Endo International (NASDAQ:ENDP) (TSE:ENL) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, May 6th. Analysts expect the company to announce earnings of $0.48 per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, February 25th. The company reported $0.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.27. The firm had revenue of $760.22 million for the quarter, compared to analysts’ expectations of $653.83 million. Endo International had a negative net margin of 5.30% and a negative return on equity of 85.80%. During the same period in the previous year, the company earned $0.74 earnings per share. On average, analysts expect Endo International to post $3 EPS for the current fiscal year and $2 EPS for the next fiscal year.
ENDP opened at $5.49 on Wednesday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -8.07 and a beta of 1.41. Endo International has a twelve month low of $2.71 and a twelve month high of $10.89. The company’s 50-day moving average price is $6.83 and its two-hundred day moving average price is $6.74.
ENDP has been the topic of a number of research analyst reports. TheStreet upgraded shares of Endo International from a “d” rating to a “c” rating in a research note on Monday, March 29th. Barclays boosted their target price on shares of Endo International from $6.00 to $7.00 and gave the company an “equal weight” rating in a research note on Monday, March 8th. Zacks Investment Research lowered shares of Endo International from a “buy” rating to a “sell” rating and set a $7.50 price target on the stock. in a research report on Tuesday, January 12th. Citigroup lowered their price target on shares of Endo International from $11.00 to $10.00 in a research report on Thursday, March 4th. Finally, Royal Bank of Canada initiated coverage on shares of Endo International in a research report on Wednesday, April 7th. They issued a “sector perform” rating and a $7.00 price target on the stock. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $7.64.
In related news, Director Shane Cooke sold 17,290 shares of the firm’s stock in a transaction that occurred on Monday, March 15th. The shares were sold at an average price of $8.65, for a total value of $149,558.50. Following the transaction, the director now owns 97,104 shares of the company’s stock, valued at $839,949.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.50% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.
Further Reading: 52 Week Highs and Lows
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.